HER2 status in breast cancer determined by IHC and FISH: Comparison of the results

Polish Journal of Pathology

Volumn 55, Issue 4, 2004, Pages 165-171

  Mrozkowiak, Anna ^a   Olszewski, Wojciech P ^a   Piaścik, Agata ^a   Olszewski, Włodzimierz T ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANEUPLOIDY; ARTICLE; BREAST CANCER; CELL MEMBRANE; CHROMOSOME 17; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLAND; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2;

EID: 14644442356     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Allred DC, Harvey JM, Berardo M: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11, 155-168.
2. Baselga J, Tripathy D, Mendesohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous trastuzumab (herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999, 26, 78-83.
3. Baselga J: Phase I and II trials of trastuzumab. Ann Oncol 2001, 12(Suppl 1), 49-55.
4. Cobleigh MA, Vogel CL, Tripathy D et al: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998, 17, 97(abs).
5. Di Fiore PP, Fleming TP: Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 1987, 51, 1063-1070.
6. Di Leo A, Cardos F, Dubercq M: Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int J Clin Oncol 2002, 7, 245-253.
7. Gaiser T, Hofmann M, Weng LP, Schmidtgen C, Maass C, Gross C, Henkel T, Ruechoff J: Her2 status determination: significance of chromosome 17 polysomy identified using 2-colour FISH. San Antonio Breast Cancer Symposium 2003, #601.
8. Gray JW, Pinkiel D: Molecular cytogenetics in human cancer diagnosis. Cancer 1992, 69, 1536-1542.
9. Hanahan D, Weinberg RA: Hallmarks of cancer. Cell 2000, 100, 57-70.
10. Hung M-C, Lau Y-K: Basic science of HER-2/neu: A review. Semin Oncol 1999, 26(Suppl 12), 51-59.
11. Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta Rev Cancer 1994, 1198, 165-184.
12. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999, 17, 1974-1982.
13. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U: HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001, 19, 354-363.
14. Lipton A, Ali SM, Leitzel K: Elevated serum level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002, 20, 1467-1472.
15. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A: HER2 as a prognostic factor in breast cancer. Oncology 2001, 61(Suppl 2), 67-72.
16. Menard S, Valagussa P, Pilotti S: Response to cyclophosphamide, methotrexate and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumour biological variables. J Clin Oncol 2001, 19, 329-335.
17. Mitchell MS, Press MF: The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999, 26(Suppl 12), 108-116.
18. Neve RM, Lane HA, Hynes NE: The role of overexpressed HER2 in transformation. Ann Oncol 2001, 12(Suppl 1), S9-S13.
19. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998, 90, 1361-1370.
20. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL. Wolmark N: HER2 and choice if adjuvant chemotherapy of invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J Natl Cancer Inst 2000, 92, 1991-1998.
21. Pauletti G, Dandekar S, Rang H, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000, 18, 3651-3664.
22. Pauletti G, Godolphin W, Press MF et al: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridisation. Oncogene 1996, 13, 63-72.
23. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J, Ma Y. Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Philips RN, Ross JS, Wolman SR, Flom KJ: HER-2/neu gene amplification characterised fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997, 15, 2894-2904.
24. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994, 54, 2771-2777.
25. Ravdin PM: Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999, 26(Suppl 12), 117-123.
26. Seshadri K, Firgaira AF, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical Significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993, 11(10), 1936-1942.
27. Slamon D, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
28. Slamon DJ, Godolphin W, Jones LA et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
29. Smith I: Future directions in the adjuvant treatment of breast cancer: The role of trastuzumab: Ann Oncol 2001, 12(Suppl 1), 75-79.
30. Thor A: HER2 - a discussion of testing approaches in the USA. Ann Oncol 2001, 12(Suppl 1), 101-107.
31. Van de Vijver MJ: Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2). Eur J Cancer 2001, 37(Suppl 1), 11-17.